Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates

Antiviral Research

Volumn 111, Issue , 2014, Pages 60-68

  Song, Aihua ^a   Myojo, Kensuke ^a   Laudenslager, John ^a   Harada, Daisuke ^a   Miura, Toru ^a   Suzuki, Kazuo ^a   Kuni Kamochi, Reiko ^a   Soloff, Rachel ^a   Ohgami, Kinya ^a   Kanda, Yutaka ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

A; Antibody; Influenza; Matrix protein 2; Therapeutic; Virus infection

Indexed keywords

AMANTADINE; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY Z3G1; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; OSELTAMIVIR; UNCLASSIFIED DRUG; ZANAMIVIR; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; CLINICAL CHEMISTRY; COMPLEMENT FIXATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; EXPERIMENTAL MONKEY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A (H3N2); INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; LETHAL DOSE; LUNG INJURY; LUNG LESION; LUNG PARENCHYMA; MALE; MICROSCOPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXYGEN SATURATION; PATHOLOGY; PLASMA HALF LIFE; THERAPY EFFECT; UPPER RESPIRATORY TRACT; VIRUS LOAD; VIRUS SHEDDING; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; IMMUNOLOGY; INFLUENZA, HUMAN; MACACA; PASSIVE IMMUNIZATION; PHYSIOLOGY; VIROLOGY;

MUS; PRIMATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MACACA; MALE; MICE; MICE, INBRED C57BL; VIRAL MATRIX PROTEINS;

EID: 84907515712     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.08.016     Document Type: Article

References (45)

1. Y. Abed, N. Goyette, and G. Boivin Generation and characterization of recombinant influenza A (H1N1) viruses harboring amantadine resistance mutations Antimicrob. Agents Chemother. 49 2005 556 559
2. R.R. Beerli, M. Bauer, N. Schmitz, R.B. Buser, M. Gwerder, S. Muntwiler, W.A. Renner, P. Saudan, and M.F. Bachmann Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein Virol. J. 6 2009 224
3. R.A. Bright, D.K. Shay, B. Shu, N.J. Cox, and A.I. Klimov Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States JAMA 295 2006 891 894
4. E.G. Brown, H. Liu, L.C. Kit, S. Baird, and M. Nesrallah Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: identification of functional themes Proc. Nat. Acad. Sci. USA 98 2001 6883 6888
5. P.J. Collins, L.F. Haire, Y.P. Lin, J. Liu, R.J. Russell, P.A. Walker, J.J. Skehel, S.R. Martin, A.J. Hay, and S.J. Gamblin Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants Nature 453 2008 1258 1261
6. D. Corti, A.L. Suguitan Jr., D. Pinna, C. Silacci, B.M. Fernandez-Rodriguez, F. Vanzetta, C. Santos, C.J. Luke, F.J. Torres-Velez, N.J. Temperton, R.A. Weiss, F. Sallusto, K. Subbarao, and A. Lanzavecchia Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine The J. Clin. Invest. 120 2010 1663 1673
7. D. Corti, J. Voss, S.J. Gamblin, G. Codoni, A. Macagno, D. Jarrossay, S.G. Vachieri, D. Pinna, A. Minola, F. Vanzetta, C. Silacci, B.M. Fernandez-Rodriguez, G. Agatic, S. Bianchi, I. Giacchetto-Sasselli, L. Calder, F. Sallusto, P. Collins, L.F. Haire, N. Temperton, J.P. Langedijk, J.J. Skehel, and A. Lanzavecchia A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins Science 333 2011 850 856
8. M. De Filette, W. Min Jou, A. Birkett, K. Lyons, B. Schultz, A. Tonkyro, S. Resch, and W. Fiers Universal influenza A vaccine: optimization of M2-based constructs Virology 337 2005 149 161
9. M.D. de Jong, T.T. Tran, H.K. Truong, M.H. Vo, G.J. Smith, V.C. Nguyen, V.C. Bach, T.Q. Phan, Q.H. Do, Y. Guan, J.S. Peiris, T.H. Tran, and J. Farrar Oseltamivir resistance during treatment of influenza A (H5N1) infection N. Engl. J. Med. 353 2005 2667 2672
10. J. Denis, E. Acosta-Ramirez, Y. Zhao, M.E. Hamelin, I. Koukavica, M. Baz, Y. Abed, C. Savard, C. Pare, C. Lopez Macias, G. Boivin, and D. Leclerc Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform Vaccine 26 2008 3395 3403
11. C. Dreyfus, N.S. Laursen, T. Kwaks, D. Zuijdgeest, R. Khayat, D.C. Ekiert, J.H. Lee, Z. Metlagel, M.V. Bujny, M. Jongeneelen, R. van der Vlugt, M. Lamrani, H.J. Korse, E. Geelen, O. Sahin, M. Sieuwerts, J.P. Brakenhoff, R. Vogels, O.T. Li, L.L. Poon, M. Peiris, W. Koudstaal, A.B. Ward, I.A. Wilson, J. Goudsmit, and R.H. Friesen Highly conserved protective epitopes on influenza B viruses Science 337 2012 1343 1348
12. D.C. Ekiert, R.H. Friesen, G. Bhabha, T. Kwaks, M. Jongeneelen, W. Yu, C. Ophorst, F. Cox, H.J. Korse, B. Brandenburg, R. Vogels, J.P. Brakenhoff, R. Kompier, M.H. Koldijk, L.A. Cornelissen, L.L. Poon, M. Peiris, W. Koudstaal, I.A. Wilson, and J. Goudsmit A highly conserved neutralizing epitope on group 2 influenza A viruses Science 333 2011 843 850
13. J. Fan, X. Liang, M.S. Horton, H.C. Perry, M.P. Citron, G.J. Heidecker, T.M. Fu, J. Joyce, C.T. Przysiecki, P.M. Keller, V.M. Garsky, R. Ionescu, Y. Rippeon, L. Shi, M.A. Chastain, J.H. Condra, M.E. Davies, J. Liao, E.A. Emini, and J.W. Shiver Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys Vaccine 22 2004 2993 3003
14. W. Fiers, M. De Filette, A. Birkett, S. Neirynck, and W. Min Jou A "universal" human influenza A vaccine Virus Res. 103 2004 173 176
15. A.G. Grandea 3rd, O.A. Olsen, T.C. Cox, M. Renshaw, P.W. Hammond, P.Y. Chan-Hui, J.L. Mitcham, W. Cieplak, S.M. Stewart, M.L. Grantham, A. Pekosz, M. Kiso, K. Shinya, M. Hatta, Y. Kawaoka, and M. Moyle Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses Proc. Nat. Acad. Sci. USA 107 2010 12658 12663
16. S. Herfst, J.M. van den Brand, E.J. Schrauwen, E. de Wit, V.J. Munster, G. van Amerongen, M. Linster, F. Zaaraoui, W.F. van Ijcken, G.F. Rimmelzwaan, A.D. Osterhaus, R.A. Fouchier, A.C. Andeweg, and T. Kuiken Pandemic 2009 H1N1 influenza virus causes diffuse alveolar damage in cynomolgus macaques Vet. Pathol. 47 2010 1040 1047
17. I.R. Humphreys, G. Walzl, L. Edwards, A. Rae, S. Hill, and T. Hussell A critical role for OX40 in T cell-mediated immunopathology during lung viral infection J. Exp. Med. 198 2003 1237 1242
18. A.C. Hurt, J.K. Holien, M.W. Parker, and I.G. Barr Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses Drugs 69 2009 2523 2531
19. A. Jegerlehner, N. Schmitz, T. Storni, and M.F. Bachmann Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity J. Immunol. 172 2004 5598 5605
20. F. Krammer, and P. Palese Influenza virus hemagglutinin stalk-based antibodies and vaccines Curr. Opin. Virol. 3 2013 521 530
21. F. Krammer, N. Pica, R. Hai, I. Margine, and P. Palese Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies J. Virol. 87 2013 6542 6550
22. W. Liu, P. Zou, J. Ding, Y. Lu, and Y.H. Chen Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design Microbes Infect. 7 2005 171 177
23. I. Margine, F. Krammer, R. Hai, N.S. Heaton, G.S. Tan, S.A. Andrews, J.A. Runstadler, P.C. Wilson, R.A. Albrecht, A. Garcia-Sastre, and P. Palese Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses J. Virol. 87 2013 10435 10446
24. K. Motoki, E. Mori, A. Matsumoto, M. Thomas, T. Tomura, R. Humphreys, V. Albert, M. Muto, H. Yoshida, M. Aoki, T. Tamada, R. Kuroki, I. Ishida, C.F. Ware, and S. Kataoka Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 Clin. Cancer Res. 11 2005 3126 3135
25. K. Mozdzanowska, J. Feng, M. Eid, G. Kragol, M. Cudic, L. Otvos Jr., and W. Gerhard Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2 Vaccine 21 2003 2616 2626
26. A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, and R. Niwa Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities Cancer Res. 68 2008 3863 3872
27. S. Neirynck, T. Deroo, X. Saelens, P. Vanlandschoot, W.M. Jou, and W. Fiers A universal influenza A vaccine based on the extracellular domain of the M2 protein Nat. Med. 5 1999 1157 1163
28. G. Palladino, K. Mozdzanowska, G. Washko, and W. Gerhard Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice J. Virol. 69 1995 2075 2081
29. Y. Prawira, D. Murniati, A. Rusli, S. Giriputro, V. Setiawaty, H. Oswari, and M. Said Clinical, laboratory, and radiologic characteristics of confirmed avian influenza (H5N1). Southeast Asian J. Trop. Med. Public Health 43 2012 877 889
30. H. Sagawa, A. Ohshima, I. Kato, Y. Okuno, and Y. Isegawa The immunological activity of a deletion mutant of influenza virus hemagglutinin lacking the globular region J. Gen. Virol. 77 Pt 7 1996 1483 1487
31. C.F. Santillan Salas, S. Mehra, M.R. Pardo Crespo, and Y.J. Juhn Asthma and severity of 2009 novel H1N1 influenza: a population-based case-control study J. Asthma 50 2013 1069 1076
32. A. Schneemann, J.A. Speir, G.S. Tan, R. Khayat, D.C. Ekiert, Y. Matsuoka, and I.A. Wilson A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin J. Virol. 86 2012 11686 11697
33. T. Shinkawa, K. Nakamura, N. Yamane, E. Shoji-Hosaka, Y. Kanda, M. Sakurada, K. Uchida, H. Anazawa, M. Satoh, M. Yamasaki, N. Hanai, and K. Shitara The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity J. Biol. Chem. 278 2003 3466 3473
34. L. Simonsen, K. Fukuda, L.B. Schonberger, and N.J. Cox The impact of influenza epidemics on hospitalizations J. Infect. Dis. 181 2000 831 837
35. J. Steel, A.C. Lowen, T.T. Wang, M. Yondola, Q. Gao, K. Haye, A. Garcia-Sastre, and P. Palese Influenza virus vaccine based on the conserved hemagglutinin stalk domain mBio 1 1 2010 e00018 10
36. K.J. Stittelaar, M. Tisdale, G. van Amerongen, R.F. van Lavieren, F. Pistoor, J. Simon, and A.D. Osterhaus Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques Antiviral Res. 80 2008 225 228
37. J. Sui, W.C. Hwang, S. Perez, G. Wei, D. Aird, L.M. Chen, E. Santelli, B. Stec, G. Cadwell, M. Ali, H. Wan, A. Murakami, A. Yammanuru, T. Han, N.J. Cox, L.A. Bankston, R.O. Donis, R.C. Liddington, and W.A. Marasco Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses Nat. Struct. Mol. Biol. 16 2009 265 273
38. W.W. Thompson, D.K. Shay, E. Weintraub, L. Brammer, N. Cox, L.J. Anderson, and K. Fukuda Mortality associated with influenza and respiratory syncytial virus in the United States JAMA 289 2003 179 186
39. C.A. Thomson, Y. Wang, L.M. Jackson, M. Olson, W. Wang, A. Liavonchanka, L. Keleta, V. Silva, S. Diederich, R.B. Jones, J. Gubbay, J. Pasick, M. Petric, F. Jean, V.G. Allen, E.G. Brown, J.M. Rini, and J.W. Schrader Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem Front. Immunol. 3 2012 87
40. M. Throsby, E. van den Brink, M. Jongeneelen, L.L. Poon, P. Alard, L. Cornelissen, A. Bakker, F. Cox, E. van Deventer, Y. Guan, J. Cinatl, J. ter Meulen, I. Lasters, R. Carsetti, M. Peiris, J. de Kruif, and J. Goudsmit Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM + memory B cells PLoS One 3 2008 e3942
41. T.M. Uyeki Global epidemiology of human infections with highly pathogenic avian influenza A (H5N1) viruses Respirology 13 Suppl 1 2008 S2 9
42. J.L. Virelizier Host defenses against influenza virus: the role of anti-hemagglutinin antibody J. Immunol. 115 1975 434 439
43. R. Wang, A. Song, J. Levin, D. Dennis, N.J. Zhang, H. Yoshida, L. Koriazova, L. Madura, L. Shapiro, A. Matsumoto, T. Mikayama, R.T. Kubo, S. Sarawar, H. Cheroutre, and S. Kato Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein Antiviral Res. 80 2008 168 177
44. S.L. Zebedee, and R.A. Lamb Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions J. Virol. 62 1988 2762 2772
45. D. Zharikova, K. Mozdzanowska, J. Feng, M. Zhang, and W. Gerhard Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2 J. Virol. 79 2005 6644 6654